North East Thames Regional Genetics Service, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
Department of Obstetrics and Gynecology, Division of Reproductive Genetics, Columbia University, New York, NY, USA.
Prenat Diagn. 2018 Jan;38(1):10-19. doi: 10.1002/pd.5102. Epub 2017 Jul 25.
Prenatal genetic diagnosis provides information for pregnancy and perinatal decision-making and management. In several small series, prenatal whole exome sequencing (WES) approaches have identified genetic diagnoses when conventional tests (karyotype and microarray) were not diagnostic. Here, we review published prenatal WES studies and recent conference abstracts. Thirty-one studies were identified, with diagnostic rates in series of five or more fetuses varying between 6.2% and 80%. Differences in inclusion criteria and trio versus singleton approaches to sequencing largely account for the wide range of diagnostic rates. The data suggest that diagnostic yields will be greater in fetuses with multiple anomalies or in cases preselected following genetic review. Beyond its ability to improve diagnostic rates, we explore the potential of WES to improve understanding of prenatal presentations of genetic disorders and lethal fetal syndromes. We discuss prenatal phenotyping limitations, counselling challenges regarding variants of uncertain significance, incidental and secondary findings, and technical problems in WES. We review the practical, ethical, social and economic issues that must be considered before prenatal WES could become part of routine testing. Finally, we reflect upon the potential future of prenatal genetic diagnosis, including a move towards whole genome sequencing and non-invasive whole exome and whole genome testing. © 2017 John Wiley & Sons, Ltd.
产前基因诊断为妊娠和围产期决策和管理提供信息。在几个小系列中,当常规检测(核型分析和微阵列)无法诊断时,产前全外显子组测序(WES)方法已经确定了遗传诊断。在这里,我们回顾了已发表的产前 WES 研究和最近的会议摘要。确定了 31 项研究,在纳入标准和 trio 与 singleton 测序方法方面存在差异,这在很大程度上解释了诊断率的广泛差异。这些数据表明,在具有多种异常的胎儿或在经过遗传审查后预先选择的情况下,诊断率将会更高。除了提高诊断率的能力之外,我们还探讨了 WES 改善对遗传疾病和致死性胎儿综合征产前表现的理解的潜力。我们讨论了产前表型限制、关于意义不明的变异、偶然和次要发现以及 WES 技术问题的咨询挑战。我们回顾了在产前 WES 成为常规检测的一部分之前必须考虑的实际、伦理、社会和经济问题。最后,我们反思了产前基因诊断的未来,包括向全基因组测序以及非侵入性全外显子组和全基因组检测的转变。 © 2017 约翰威立父子公司